Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
Completed
Hoffmann-La Roche
Phase 3
1969-12-31
To determine the efficacy of acitretin in the treatment of psoriasis in HIV/AIDS patients.
Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with
psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of
etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in
treating psoriasis in patients without HIV infection by reducing skin involvement and
clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients.
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
Completed
M.D. Anderson Cancer Center
Phase 2
1990-05-08
The purpose of this study is to determine the response rate of patients with T-cell
malignancies to combination therapy using interferon-alpha (Roferon) and Isotretinoin
(Accutane).
Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
Completed
Fundação de Amparo à Pesquisa do Estado de São Paulo
Phase 4
2014-08-01
The purpose of this study is to assess whether the switch from branded to generic warfarin or
between different generic warfarin tablets may cause fluctuation in the results of
coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing
them to unnecessary risks.
Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
Completed
Federal University of São Paulo
Phase 4
2014-08-01
The purpose of this study is to assess whether the switch from branded to generic warfarin or
between different generic warfarin tablets may cause fluctuation in the results of
coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing
them to unnecessary risks.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
